News for Arcus Biosciences, Inc. (RCUS)

On May 9, 2025, Morgan Stanley, led by analyst Terence Flynn, updated its assessment of Arcus Biosciences (RCUS), maintaining its "Overweight" rating. Despite r

Wells Fargo analyst Eva Fortea Verdejo has revised the firm's target price for Arcus Biosciences (RCUS), lowering it from $29 to $26 while maintaining an Overwe

Cash Position: $1 billion as of the end of the first quarter 2025, compared to $992 million at the end of 2024.Equity Financing: $150 million completed in Febr

May 06, 2025 / 08:30PM GMTOperator Hello, everyone. And welcome to Arcus Biosciences first quarter 2025 earnings and financial results call. My name is Lydia, a

Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ETCompany ParticipantsPia Eaves - VP, IRTerry Rosen - CEORichard...

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -11.76% and 14.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapie

Arcus Biosciences (RCUS) Q1 results: GAAP EPS of -$1.14 & $28M revenue miss estimates.

U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday. Shares of Ichor Holdings, Ltd. ICHR fell sharply in today'...

Arcus Biosciences Inc (RCUS) is set to release its Q1 2025 earnings on May 6, 2025. The consensus estimate for Q1 2025 revenue is $0.04 billion, and the earning

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapie

Arcus Biosciences (RCUS) has granted new employment inducement options and restricted stock units to three employees. The options cover a total of 39,75

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapie

Arcus Biosciences (RCUS) to present new data at the 2025 ASCO Annual Meeting. First combination data for HIF-2a inhibitor casdatifan and cabozantinib to be

Barclays analyst Peter Lawson has significantly reduced the price target for Arcus Biosciences (RCUS), bringing it down to $14 from the previous target of $29.

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for

We recently published a list of the 11 Cheap NASDAQ Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapie

Arcus Biosciences (RCUS) grants stock options and restricted stock units to new employees. The stock options cover 16,960 shares at $7.04 per share, the